ライフサイエンスコーパス: estrogen replacement

1 2) rats with OVX; and 3) rats with OVX with estrogen replacement.

2 ctomy (OVX) that are or are not treated with estrogen replacement.

3 n report impaired sexual functioning despite estrogen replacement.

4 ce the risk of breast cancer associated with estrogen replacement.

5 sEH was increased in the kidney with estrogen replacement.

6 significantly by ovariectomy and reversed by estrogen replacement.

7 ocked in ovariectomized rats and elevated by estrogen replacement.

8 of BrdU-labeled cells, an effect reversed by estrogen replacement.

9 zed by ovariectomy and reversed partially by estrogen replacement.

10 benefits associated with early initiation of estrogen replacement.

11 b of the diagonal band of Broca after ovx or estrogen replacement.

12 ized with (OVX+E, n=6) or without (OVX, n=8) estrogen replacement.

13 gnificantly increased in the heart following estrogen replacement.

14 , or old [24-26 months]) and with or without estrogen replacement.

15 ere part of a randomized controlled trial of estrogen replacement.

16 tomized females, ovariectomized females with estrogen replacement (10 microg 17beta-estradiol in 100

17 ariectomy (31 +/- 7) and totally reversed by estrogen replacement (110 +/- 23).

18 Estrogen replacement (17beta-estradiol subcutaneous pell

19 ers from ovariectomized rats with or without estrogen replacement after 4 weeks of continuous ethanol

20 bout negative overall health consequences of estrogen replacement after menopause have led to the ado

21 nary artery disease who were enrolled in the Estrogen Replacement and Atherosclerosis trial with resp

22 opausal women (n = 229) participating in the Estrogen Replacement and Atherosclerosis trial.

23 male ovariectomized rats were provided acute estrogen replacement and the number of cortical GABA, ER

24 r trends, hematologic factors, homocysteine, estrogen replacement, and familial and genetic factors.

25 female dentate granule cells with long-term estrogen replacement at either high or low levels still

26 hyperparathyroidism have included the use of estrogen replacement, bisphosphonates, and a new class o

27 Whether or not long-term estrogen replacement can enhance basal forebrain choline

28 Recent studies have shown that estrogen replacement can enhance the functional status o

29 Studies suggest that estrogen replacement can influence learning and memory p

30 rthermore, it is not known whether childhood estrogen replacement combined with growth hormone therap

31 am surgery compared to OVX or after OVX plus estrogen replacement compared to OVX plus placebo treatm

32 Group 1 (n = 24) had no estrogen replacement (control), group 2 (n = 22) receive

33 Short-term estrogen replacement decreased cocaine-induced ambulatio

34 Likewise, estrogen replacement did not prevent a decrease in ChAT-

35 These data suggest that estrogen replacement does not protect cholinergic neuron

36 Estrogen replacement fails to block M-CSF mRNA expressio

37 zed rats that were either untreated or given estrogen replacement for 4 weeks.

38 ol metabolite of equine estrogens present in estrogen replacement formulations, autoxidizes to a redo

39 Short-term estrogen replacement has been shown to enhance basal for

40 Because long-term estrogen replacement has been shown to have no effect on

41 e at lower risk because of never having used estrogen replacement hormones.

42 and senescence and was partially restored by estrogen replacement, implicating ovarian hormones in th

43 Estrogen replacement in aged female rats failed to incre

44 In experiment 2, estrogen replacement in ovariectomized female rats reduc

45 ortant implications for cognitive effects of estrogen replacement in postmenopausal women and demonst

46 plasma estrogen level to drop 100-fold, the estrogen replacement in preterm infants is physiological

47 at androgen treatment may be as effective as estrogen replacement in reversing the decline in hippoca

48 women outweighs current evidence for use of estrogen replacement in this setting.

49 Systemic estrogen replacement (in the form of hormone replacement

50 Estrogen replacement increases both the number of dendri

51 model to test whether surgical menopause and estrogen replacement influence the cognitive outcome of

52 tion was unaffected by OVX but enhanced with estrogen replacement (intact, 55+/-8; OVX, 59+/-7; OVX+E

53 tion was diminished by OVX and restored with estrogen replacement (intact, 82+/-7; OVX, 61+/-9; OVX+E

54 ts in this report were part of a prospective estrogen replacement interventional study.

55 Postmenopausal estrogen replacement is associated with an increased ris

56 Whether estrogen replacement is beneficial to cognitive health i

57 Estrogen replacement is known to manifest bone protectiv

58 Postmenopausal estrogen replacement is widely used in the United States

59 We speculate that estrogen replacement might ameliorate disruption in prod

60 We speculate that estrogen replacement might partially restore neurogenesi

61 udies with ovariectomized and ovariectomized/estrogen replacement mouse models demonstrated that HDL-

62 The protective effect of estrogen replacement on ascending urinary-tract infectio

63 presence of estrogen, the effects of ovx and estrogen replacement on ChAT mRNA levels were also exami

64 The effects of one week of estrogen replacement on choline acetyltransferase (ChAT)

65 s can contribute to the effects of long-term estrogen replacement on cognitive performance recently d

66 s may, in turn, contribute to the effects of estrogen replacement on hippocampal connectivity and cog

67 s study demonstrates a significant effect of estrogen replacement on IGF system components in synovia

68 the effects of gonadectomy with and without estrogen replacement on the mRNA and protein of BDNF and

69 termined the effect of ovariectomy (OVX) and estrogen replacement on the ultrastructural localization

70 termine the effects of ovariectomy (ovx) and estrogen replacement on trkA mRNA levels in the rat basa

71 We studied the effect of ovariectomy and estrogen replacement on tumor formation in C57BL/6J-Min/

72 ctomized Sprague-Dawley rats received either estrogen replacement or sham surgery, and then received

73 r OVX rats receiving physiological levels of estrogen replacement (OVX+E group).

74 tomized (OVX), 4) old OVX, 5) young OVX plus estrogen replacement (OVX+E2), and 6) old OVX+E2.

75 three groups: ovariectomized (OVX), OVX with estrogen replacement (OVX+E2), or sham OVX (tested in di

76 that were neither castrated nor treated with estrogen replacement (P = 0.85).

77 Estrogen replacement partially restores this benefit of

78 t neither 3 weeks nor 13 weeks of continuous estrogen replacement prevented the loss of choline acety

79 Estrogen replacement prevents these effects, indicating

80 ells isolated from ethanol-treated rats with estrogen replacement produced more tumor necrosis factor

81 These findings demonstrate that (1) estrogen replacement produces regionally selective effec

82 postmenopausal women and demonstrate that an estrogen replacement protocol that mimics normal physiol

83 The data indicate that the cyclic estrogen replacement regimen does not influence spatial

84 mphasizes the need to investigate a periodic estrogen replacement regimen to reduce cognitive decline

85 interleukin-6 (IL-6), we determined whether estrogen replacement regulates the levels of these facto

86 were reduced in female Cyp2j5 (-/-) mice and estrogen replacement restored blood pressure and vascula

87 verloaded mice after ovary removal; however, estrogen replacement restored the effectiveness of silde

88 ning, and long-term (days) androgen, but not estrogen, replacement restored these parameters of AR im

89 , the density calculations showed that brief estrogen replacement restores the density of tyrosine hy

90 females results in increased mortality, and estrogen replacement results in decreased mortality in b

91 among the loss of ovarian steroid hormones, estrogen replacement, seizures, and seizure-induced cell

92 Fos expression in animals which had received estrogen replacement showed no change in response to i.c

93 Estrogen replacement significantly decreased NGF protein

94 dihydrotestosterone (DHT) had no effect, but estrogen replacement significantly increased aconitase a

95 ological age as the 19-month post-OVX group, estrogen replacement significantly increased synaptic fu

96 -up were contacted, and their menopausal and estrogen replacement status was determined.

97 Furthermore, estrogen replacement stimulated early postischemic expre

98 rcome alpha-fetoprotein sequestration of E2, estrogen replacement studies during development have use

99 mised controlled trial of HRT use, the Heart Estrogen Replacement Study (HERS).

100 Here, we showed that estrogen replacement substantially suppresses binge-like

101 Women using unopposed estrogen replacement therapy (ERT) (exclusive ERT use),

102 ars) were grouped according to HRT received: estrogen replacement therapy (ERT) (n = 13), combined (e

103 logic studies suggest a protective effect of estrogen replacement therapy (ERT) against the developme

104 d with EPRT is substantially higher than for estrogen replacement therapy (ERT) alone.

105 nction in 14 post-menopausal women receiving estrogen replacement therapy (ERT) and 48 post-menopausa

106 ated that women who have used postmenopausal estrogen replacement therapy (ERT) are at reduced risk o

107 ociation between endometrial cancer risk and estrogen replacement therapy (ERT) by CYP17 genotype usi

108 SND, however, has not been recorded during estrogen replacement therapy (ERT) in humans.

109 Estrogen replacement therapy (ERT) in postmenopausal wom

110 Clinical trials have shown estrogen replacement therapy (ERT) is associated with ad

111 nd, therefore, it has been hypothesized that estrogen replacement therapy (ERT) may have a role in pr

112 g-term (2 years) effects of estrogen loss or estrogen replacement therapy (ERT) on cholinergic neuron

113 umerous epidemiological studies suggest that estrogen replacement therapy (ERT) reduces cancer risk i

114 Although observational studies suggest that estrogen replacement therapy (ERT) reduces cardiovascula

115 Clinical studies have shown that estrogen replacement therapy (ERT) reduces the incidence

116 Some studies have shown that estrogen replacement therapy (ERT) relieves memory impai

117 The association of estrogen replacement therapy (ERT) with cognitive functi

118 luteal) women, older postmenopausal women on estrogen replacement therapy (ERT), and older postmenopa

119 intake after age 60 y, body weight, current estrogen replacement therapy (ERT), and past oral contra

120 Estrogen replacement therapy (ERT), composed of equileni

121 at menarche, parity, oral contraceptive use, estrogen replacement therapy (ERT), or history of oophor

122 on to the duration and the recency of use of estrogen replacement therapy (ERT), simultaneously inclu

123 er users as well as by total years of use of estrogen replacement therapy (ERT).

124 h 12 postmenopausal women who were not using estrogen replacement therapy (ERT).

125 at 14 months after treatment with placebo or estrogen replacement therapy (ERT).

126 The increased incidence may be delayed by estrogen replacement therapy (ERT).

127 We investigated whether the route of estrogen replacement therapy (ET) is the major determina

128 Hormone/estrogen replacement therapy (HRT/ERT) has a positive ef

129 Estrogen replacement therapy after first myocardial infa

130 Estrogen replacement therapy after myocardial infarction

131 isk for reinfarction associated with current estrogen replacement therapy after myocardial infarction

132 provides reassurance regarding the safety of estrogen replacement therapy after myocardial infarction

133 Estrogen replacement therapy and hormonal replacement th

134 attempted to determine the relation between estrogen replacement therapy and the rate of restenosis

135 es evaluating endogenous estrogen levels and estrogen replacement therapy and their relation to the o

136 Estrogen replacement therapy appears to delay the onset

137 Since estrogen replacement therapy benefits the outcome of cer

138 These results suggest a mechanism by which estrogen replacement therapy can delay or prevent AD.

139 Epidemiological studies indicate that estrogen replacement therapy decreases the risk of cardi

140 Estrogen replacement therapy enhances mood, delays cogni

141 Estrogen replacement therapy for 1 year did not slow dis

142 disorders, and provide another rationale for estrogen replacement therapy for postmenopausal women.

143 verse effect and raise concern for long term estrogen replacement therapy for stroke prevention, thes

144 is now strong epidemiological evidence that estrogen replacement therapy has a protective effect in

145 Estrogen replacement therapy has also been shown to sign

146 onducted clinical trials have indicated that estrogen replacement therapy has an adverse effect and r

147 Although estrogen replacement therapy has been associated with re

148 These findings suggest long-term estrogen replacement therapy has effects on cardiovascul

149 The importance of postmenopausal estrogen replacement therapy in affording protection aga

150 Previously, we have shown that estrogen replacement therapy in postmenopausal women dec

151 Several studies have suggested that estrogen replacement therapy in postmenopausal women imp

152 Estrogen replacement therapy in postmenopausal women is

153 raised concern for the protective effect of estrogen replacement therapy in postmenopausal women.

154 ese findings have important implications for estrogen replacement therapy in the context of aging.

155 Ovariectomized Sprague-Dawley rats received estrogen replacement therapy in the form of subcutaneous

156 or binding was significantly increased after estrogen replacement therapy in the right prefrontal cor

157 One possible outcome of estrogen replacement therapy in vivo could be reduction

158 Although estrogen replacement therapy in women has been associate

159 Estrogen replacement therapy in women is associated with

160 Estrogen replacement therapy increases plasma concentrat

161 nd clinical trials consistently suggest that estrogen replacement therapy is associated with benefici

162 In observational studies, estrogen replacement therapy is associated with decrease

163 Because estrogen replacement therapy is known to restore some im

164 t estrogen also has positive effects even if estrogen replacement therapy is not a cure-all.

165 om small clinical trials have suggested that estrogen replacement therapy may be useful for the treat

166 rmed the suggestion from animal studies that estrogen replacement therapy may have an inverse relatio

167 Epidemiologic studies have suggested that estrogen replacement therapy may lower the risk of osteo

168 Recent studies indicate that postmenopausal estrogen replacement therapy may prevent or delay the on

169 tion of Abeta40/42 peptides, suggesting that estrogen replacement therapy may protect women against t

170 ent study do not support the hypothesis that estrogen replacement therapy may slow age-related cognit

171 reast cancer, and that alcohol combined with estrogen replacement therapy may synergistically enhance

172 logical data suggest a protective effect for estrogen replacement therapy on colon cancer.

173 e of this study was to assess the effects of estrogen replacement therapy on long-term outcome, inclu

174 The effects of estrogen replacement therapy on prognosis in women with

175 trials have mainly focused on the effect of estrogen replacement therapy on the primary and secondar

176 ngs that adding progestins to postmenopausal estrogen replacement therapy protects against endometria

177 l epidemiological studies have reported that estrogen replacement therapy protects against the develo

178 Short-term estrogen replacement therapy restored trkA mRNA expressi

179 In contrast, estrogen replacement therapy significantly increased med

180 Estrogen replacement therapy significantly increased med

181 This study demonstrates the potential for estrogen replacement therapy to reduce angiographic meas

182 he relation of endogenous estrogen levels or estrogen replacement therapy to the risk of poor cogniti

183 establishing the initiation and duration of estrogen replacement therapy use as a means to prevent c

184 the combination of higher breast density and estrogen replacement therapy use.

185 ed with the combination of dense breasts and estrogen replacement therapy use; there was little diffe

186 for nondense breasts and 74% (180 of 244) in estrogen replacement therapy users and 81% (417 of 513)

187 ommendations in women aged 40-49 years or in estrogen replacement therapy users.

188 available regarding the relative benefits of estrogen replacement therapy versus reductase inhibitors

189 all-cause mortality associated with current estrogen replacement therapy was 0.50 (95% CI 0.25-1.00)

190 s 0.50 (95% CI 0.25-1.00), and that for past estrogen replacement therapy was 0.79 (95% CI 0.56-1.09)

191 interval (CI) 0.32-1.30), and that for past estrogen replacement therapy was 0.90 (95% CI 0.62-1.31)

192 Estrogen replacement therapy was associated with an impr

193 lity as well as data on age, height, weight, estrogen replacement therapy, and menopause status were

194 Epidemiologic studies of women who take estrogen replacement therapy, however, consistently repo

195 varied significantly with ethnicity, use of estrogen replacement therapy, mammographic breast densit

196 t recent hormonal therapy, chemotherapy, and estrogen replacement therapy.

197 cording to current use or duration of use of estrogen replacement therapy.

198 and grain intake, aspirin use and, in women, estrogen replacement therapy.

199 s in rats with OVX that are or are not given estrogen replacement therapy.

200 ults differed substantially for women taking estrogen replacement therapy.

201 reased fracture risk that can be reversed by estrogen replacement therapy.

202 17-one (equilin), an equine estrogen used in estrogen replacement therapy.

203 beneficial effect may be prevented by use of estrogen replacement therapy.

204 th [(18)F]deuteroaltanserin before and after estrogen replacement therapy.

205 iectomized, and half of the animals received estrogen replacement therapy.

206 women who were receiving oral or transdermal estrogen-replacement therapy (44 of whom were receiving

207 Female gender and estrogen-replacement therapy in postmenopausal women are

208 Observational studies have suggested that estrogen-replacement therapy may reduce a woman's risk o

209 enopausal women, whether they were receiving estrogen-replacement therapy or not.

210 ng aspirin, antihypertensive medication, and estrogen-replacement therapy.

211 Treatments other than estrogen replacement to alleviate HF are needed.

212 uite frequently in postmenopausal women, but estrogen replacement to correct these CNS disorders is a

213 elevance of these effects to the ability for estrogen replacement to enhance cholinergic activity and

214 in young adult rats prevents the ability of estrogen replacement to increase synaptic function in th

215 Unexpectedly, we report that exogenous estrogen replacement to ovariectomised mice in the absen

216 The present study examined the ability of estrogen replacement to protect basal forebrain choliner

217 Remarkably, estrogen replacement was found to increase long-term pot

218 However, by 19 months post-OVX, the same estrogen replacement was unable to induce these changes.

219 Using ovariectomy with or without estrogen replacement, we also demonstrated that SRC-2 KO

220 (E2; n = 8) or not receiving (NO E2; n = 9) estrogen replacement were compared with age- and BMI-mat

221 This suggests that estrogen replacement will slow but not prevent the progr

222 sults suggest that such women should not use estrogen replacement with an expectation of cardiovascul

223 ung and aged hippocampi react differently to estrogen replacement, with the aged animals unable to mo

224 al ethanol feeding model, and if so, whether estrogen replacement would compensate.